AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J.
Right arrow Articles by Andes, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J.
Right arrow Articles by Andes, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1570-1572, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1570-1572.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Voriconazole Therapeutic Drug Monitoring

J. Smith,1 N. Safdar,1 V. Knasinski,1 W. Simmons,2 S. M. Bhavnani,3 P. G. Ambrose,3 and D. Andes1,4*

University of Wisconsin, Department of Medicine, Section of Infectious Diseases, Madison, Wisconsin,1 University of Wisconsin, Department of Pharmacy, Madison, Wisconsin,2 Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York,3 University of Wisconsin, Department of Medical Microbiology and Immunology, Madison, Wisconsin4

Received 22 September 2005/ Returned for modification 4 December 2005/ Accepted 9 January 2006

We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 µg/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 µg/ml.

* Corresponding author. Mailing address: 600 Highland Avenue, Room H4/572, Madison, WI 53792. Phone: (608) 263-1545. Fax: (608) 263-4464. E-mail: dra{at}medicine.wisc.edu.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1570-1572, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1570-1572.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.